A new way to deliver protective antibodies against COVID-19 was tested in a Phase I clinical trial. Instead of injecting ...

INOVIO’s DNA medicines platform combines proprietary DNA plasmid design with CELLECTRA delivery technology, enabling cells to ...

For Research Use Only. Not for use in diagnostic procedures. The purification of plasmid DNA (pDNA) is essential in molecular biology research. Over the years, plasmid DNA isolation technology has ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

Hopewell-based team delivers on ProBio's promise of speed, quality, and reliability—offering a transparent, fixed-cost model and ≥85% supercoiled plasmid DNA in record time for clinical programs. At ...

Key market opportunities in DNA cancer vaccines include their safety, stability, and potential for personalization. Over 20 vaccines are in trials with innovations in delivery and partnerships driving ...

Plasmid DNA purification techniques have evolved significantly in response to the growing demand for high‐quality nucleic acids in gene therapy and vaccine production. Classical methods, including ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...